Small Molecule Drugs Development for Ovarian Cancer

Small molecule drugs for ovarian cancer treatment improve therapeutic efficacy by targeting specific molecular pathways within tumor cells, thereby inhibiting cancer growth and spread. Alfa Cytology is committed to advancing ovarian cancer therapy through dedicated research and development of these small molecule drugs.

Overview of Small Molecule Drugs

Small molecule drugs for ovarian cancer treatment achieve precise anti-tumor effects by targeting specific molecular pathways. These drugs interfere with key biological processes, such as cell proliferation, apoptosis, and angiogenesis, effectively inhibiting cancer cell growth and spread. By focusing on specific targets within tumor cells, small molecule drugs can slow tumor progression and enhance therapeutic efficacy. Ongoing research into these mechanisms underscores the growing importance of small molecule drugs in the treatment of ovarian cancer.

Fig 1. The damaging effects of chemotherapy drugs on the ovary and potential protectants against that damage. (SPEARS N, et al., 2019)

Pipeline of Ovarian Cancer Small Molecule Drugs

Outlined below is a comprehensive pipeline showcasing various molecules currently under development for the treatment and management of ovarian cancer.

Company	Targets	Name	Phase
Pfizer	PARP Inhibitor	PF-07104091
GlaxoSmithKline	Poly (ADP-ribose) Polymerase (PARP) 1/2 Inhibitor	Niraparib Zejula
Novartis	PI3K-alpha Inhibitor	Piqray®
ImmunoGen	FRα	GLORIOSA

Our Services

Alfa Cytology is devoted to developing and researching small molecule drugs specifically targeting ovarian cancer. We focus on uncovering the molecular mechanisms within tumor cells and designing targeted therapies to precisely inhibit cancer growth and metastasis. Through continuous innovation and comprehensive research, we aim to significantly advance the field of ovarian cancer treatment.

Workflow of Small Molecule Drugs Development

Target Identification and Validation

Identify and experimentally validate biological targets that are crucial in the development and progression of ovarian cancer to confirm their significant role in the disease's pathophysiology.

Compound Discovery

Ovarian cancer active candidate molecules are meticulously identified from extensive compound libraries through the application of advanced high-throughput screening techniques, ensuring the selection of potential successful drug candidates.

Drug Optimization

Enhance the chemical structures of identified ovarian cancer drug candidates through detailed refinement processes to significantly boost therapeutic efficacy and minimize adverse side effects, building upon findings from preliminary studies.

Preclinical Research

Preclinical research for small molecule drug development involves extensive laboratory and animal testing to evaluate the safety, efficacy, and biological activity of potential drug candidates. This stage is crucial for understanding the pharmacokinetics, pharmacodynamics, and toxicology profiles, helping to predict how the drug might behave in humans.

Assays for Small Molecule Drugs

Small molecule drugs have demonstrated a wide range of potential applications and significant therapeutic value across a variety of experimental studies in the treatment of ovarian cancer.

Cell-Based Assays for Ovarian Cancer

Signaling Pathway Analysis for Ovarian Cancer

Omics Services for Ovarian Cancer

Ovarian Cancer Pathogenesis Analysis

Tumor Microenvironment Analysis

More

Alfa Cytology is steadfastly committed to advancing the research and development of small molecule drugs for ovarian cancer through the efforts of our specialized research team. If you have any questions about our services, please do not hesitate to contact us.

Reference

SPEARS N, LOPES F, STEFANSDOTTIR A, et al. Ovarian damage from chemotherapy and current approaches to its protection [J]. Hum Reprod Update, 2019, 25(6): 673-93.

! For research use only.